Northern Trust Corp Lowers Stock Holdings in Regulus Therapeutics Inc. (NASDAQ:RGLS)

Northern Trust Corp decreased its holdings in Regulus Therapeutics Inc. (NASDAQ:RGLS - Free Report) by 8.1% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 457,233 shares of the biopharmaceutical company's stock after selling 40,071 shares during the quarter. Northern Trust Corp owned 0.70% of Regulus Therapeutics worth $722,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also bought and sold shares of RGLS. Barclays PLC raised its position in shares of Regulus Therapeutics by 13.9% in the fourth quarter. Barclays PLC now owns 96,247 shares of the biopharmaceutical company's stock valued at $152,000 after buying an additional 11,770 shares in the last quarter. Renaissance Technologies LLC increased its holdings in Regulus Therapeutics by 20.5% in the 4th quarter. Renaissance Technologies LLC now owns 117,100 shares of the biopharmaceutical company's stock valued at $185,000 after buying an additional 19,900 shares during the period. JPMorgan Chase & Co. lifted its stake in shares of Regulus Therapeutics by 193.4% in the 3rd quarter. JPMorgan Chase & Co. now owns 78,972 shares of the biopharmaceutical company's stock valued at $124,000 after acquiring an additional 52,059 shares during the last quarter. Finally, PEAK6 LLC acquired a new position in shares of Regulus Therapeutics during the fourth quarter worth $95,000. Institutional investors and hedge funds own 92.38% of the company's stock.

Regulus Therapeutics Price Performance

NASDAQ RGLS traded up $0.01 during trading on Wednesday, reaching $7.98. The company's stock had a trading volume of 78,822 shares, compared to its average volume of 907,080. Regulus Therapeutics Inc. has a one year low of $0.83 and a one year high of $8.20. The firm has a fifty day moving average of $4.98 and a 200 day moving average of $2.64. The stock has a market capitalization of $552.14 million, a PE ratio of -7.45 and a beta of 0.49.

Regulus Therapeutics (NASDAQ:RGLS - Get Free Report) last issued its earnings results on Thursday, May 8th. The biopharmaceutical company reported ($0.15) EPS for the quarter, topping analysts' consensus estimates of ($0.29) by $0.14. Research analysts expect that Regulus Therapeutics Inc. will post -0.88 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on RGLS. Leerink Partners reissued a "market perform" rating and issued a $7.00 price target on shares of Regulus Therapeutics in a research note on Wednesday, April 30th. Jones Trading reissued a "hold" rating and issued a $7.00 price objective (down from $8.00) on shares of Regulus Therapeutics in a research note on Wednesday, April 30th. HC Wainwright reaffirmed a "buy" rating and set a $10.00 target price on shares of Regulus Therapeutics in a research note on Friday, March 14th. Canaccord Genuity Group reaffirmed a "hold" rating and set a $11.00 price target (down from $28.00) on shares of Regulus Therapeutics in a research note on Wednesday, April 30th. Finally, Leerink Partnrs lowered shares of Regulus Therapeutics from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, April 30th. One research analyst has rated the stock with a sell rating, five have given a hold rating and two have issued a buy rating to the company. According to MarketBeat.com, Regulus Therapeutics has a consensus rating of "Hold" and an average price target of $8.50.

Regulus Therapeutics Company Profile

Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.